Demographics and disease characteristics of patients randomized in consolidation
| . | Treatment . | P . | |||
|---|---|---|---|---|---|
| Standard . | Investigational . | ||||
| N . | % . | N . | % . | ||
| Age, y | |||||
| < 50 | 74 | 56.1 | 72 | 52.2 | |
| ≥ 50 | 58 | 43.9 | 66 | 47.8 | .52 |
| Median (range) | 47 (18-60) | 48 (18-60) | .74 | ||
| Sex | |||||
| Male | 64 | 48.5 | 64 | 46.4 | |
| Female | 68 | 51.5 | 74 | 53.6 | .73 |
| Peripheral WBC count, mm−3 × 1000 | |||||
| < 10 000 | 56 | 42.4 | 66 | 47.8 | |
| ≥ 10 000 | 177 | 53.6 | 171 | 52.3 | .37 |
| Median (range) | 11 (1-190) | 12 (1-179) | .69 | ||
| Hemoglobin, g/dL | |||||
| < 10 | 91 | 68.9 | 91 | 65.9 | |
| ≥ 10 | 98 | 29.7 | 91 | 27.8 | .60 |
| Median (range) | 9 (5-30) | 9 (5-15) | .86 | ||
| Peripheral platelet count mm−3 × 1000 | |||||
| < 50 000 | 68 | 51.5 | 69 | 50.0 | |
| ≥ 50 000 | 177 | 53.6 | 170 | 52.0 | .80 |
| Median (range) | 48 (1-479) | 50 (9-452) | .79 | ||
| Cytogenetics | |||||
| Favorable | 27 | 20.5 | 32 | 23.2 | |
| Indeterminate | 89 | 27.0 | 85 | 26.0 | |
| Intermediate | 44 | 33.3 | 37 | 26.8 | |
| Unfavorable | 52 | 39.4 | 59 | 42.8 | .77 |
| FLT3-ITD | |||||
| Unknown/missing | 6 | 4.5 | 11 | 8.0 | |
| Negative | 96 | 72.7 | 96 | 69.6 | |
| Positive | 30 | 22.7 | 31 | 22.5 | .91 |
| Median peripheral blasts (range) | 326 (0%-98) | 32 (0-99) | .22 | ||
| Median marrow blasts (range) | 69 (9-100) | 59 (3-100) | .13 | ||
| Median CD33 intensity, MFI ratio (range) | 48.62 (1-481) | 62.6 (3-802) | |||
| Median CD33+ blasts (range) | 99.0 (0-99) | 99.0 (70-99) | |||
| Median peripheral neutrophils (range) | 10 (0-951) | 11 (0-676) | .54 | ||
| . | Treatment . | P . | |||
|---|---|---|---|---|---|
| Standard . | Investigational . | ||||
| N . | % . | N . | % . | ||
| Age, y | |||||
| < 50 | 74 | 56.1 | 72 | 52.2 | |
| ≥ 50 | 58 | 43.9 | 66 | 47.8 | .52 |
| Median (range) | 47 (18-60) | 48 (18-60) | .74 | ||
| Sex | |||||
| Male | 64 | 48.5 | 64 | 46.4 | |
| Female | 68 | 51.5 | 74 | 53.6 | .73 |
| Peripheral WBC count, mm−3 × 1000 | |||||
| < 10 000 | 56 | 42.4 | 66 | 47.8 | |
| ≥ 10 000 | 177 | 53.6 | 171 | 52.3 | .37 |
| Median (range) | 11 (1-190) | 12 (1-179) | .69 | ||
| Hemoglobin, g/dL | |||||
| < 10 | 91 | 68.9 | 91 | 65.9 | |
| ≥ 10 | 98 | 29.7 | 91 | 27.8 | .60 |
| Median (range) | 9 (5-30) | 9 (5-15) | .86 | ||
| Peripheral platelet count mm−3 × 1000 | |||||
| < 50 000 | 68 | 51.5 | 69 | 50.0 | |
| ≥ 50 000 | 177 | 53.6 | 170 | 52.0 | .80 |
| Median (range) | 48 (1-479) | 50 (9-452) | .79 | ||
| Cytogenetics | |||||
| Favorable | 27 | 20.5 | 32 | 23.2 | |
| Indeterminate | 89 | 27.0 | 85 | 26.0 | |
| Intermediate | 44 | 33.3 | 37 | 26.8 | |
| Unfavorable | 52 | 39.4 | 59 | 42.8 | .77 |
| FLT3-ITD | |||||
| Unknown/missing | 6 | 4.5 | 11 | 8.0 | |
| Negative | 96 | 72.7 | 96 | 69.6 | |
| Positive | 30 | 22.7 | 31 | 22.5 | .91 |
| Median peripheral blasts (range) | 326 (0%-98) | 32 (0-99) | .22 | ||
| Median marrow blasts (range) | 69 (9-100) | 59 (3-100) | .13 | ||
| Median CD33 intensity, MFI ratio (range) | 48.62 (1-481) | 62.6 (3-802) | |||
| Median CD33+ blasts (range) | 99.0 (0-99) | 99.0 (70-99) | |||
| Median peripheral neutrophils (range) | 10 (0-951) | 11 (0-676) | .54 | ||
WBC indicates white blood cell; PB, peripheral blood; and BM, bone marrow.